Indian Drugmaker Targets Global Weight Loss Market

Hetero Labs, a major privately held pharmaceutical company in India, is strategically targeting the global market for generic weight-loss and diabetes drugs. The company plans to distribute 1.5 million pens of these medications within its first year of sales, with an ambitious rollout planned across more than 75 countries over the next few years.

The Hyderabad-based firm introduced injectable semaglutide last month under the brand names Truglyx, Rolmodl, and Moto G. Initial export plans encompass regions in Africa, Asia, and the Middle East. Semaglutide, the key ingredient in popular medications like Novo Nordisk's Wegovy and Ozempic, became available in India following its patent expiration in March. This has opened the door for numerous local manufacturers, with some offering substantial discounts.

Hetero's Managing Director, Vamsi Krishna Bandi, indicated a focus on building international market share before concentrating on India, with a planned domestic launch in April. The company, renowned for its cost-effective HIV treatments, will prioritize smaller markets such as Kenya, Uganda, Cambodia, and Vietnam before expanding into larger economies like Indonesia and Saudi Arabia. They are also seeking regulatory approval to enter the Canadian market.

Industry analysts project the global obesity drug market could reach approximately $100 billion by 2030. Hetero's strategy emphasizes supply efficiency, with a target monthly price of $40 to $60, deemed ideal for emerging markets. Other major players, including Dr Reddy's, have also announced aggressive sales targets for their versions of the drug.